Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Steve Fancy who wrote (5312)	9/16/1998 1:27:00 AM
From: John Metcalf	Read Replies (3) \| Respond to of 6136

Steve, it's a lot of people in a growing age-range. There are 1.7mm Americans with AMD, 10% of whom have wet AMD. That's 170,000 people in the US. Laser photocoagulation is appropriate for only 15% of these, and even so does not stop blood vessels from forming again. The incidence of AMD is three times as great for people 75 years and older as for people 65-75. As our population ages, these will become very large numbers of people. AG3340 inhibits the formation of blood vessels. The Phase II trial announced today should yield information on best dosing, viz., whether it is best used for a short course, on an intermittent basis, or always. (Perhaps I overlooked indicators from Ph I that suggest an answer to this.) Today's release also talked about AG3340 in Ph II/III trials for prostate ca and metastatic NSCL, in combination with chemotherapeutic agents. If AG3340 inhibits angiogenesis, the course of chemo might be changed, as one drug changes the environment in which the other has effects. Finally, these trials on different tissues point to a non-selective mechanism. What else will be affected?